• Login
    View Item 
    •   ORKA Home
    • Conditions, Lifestyle Factors & Interventions
    • Conditions
    • Depressive Disorders
    • View Item
    •   ORKA Home
    • Conditions, Lifestyle Factors & Interventions
    • Conditions
    • Depressive Disorders
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Real-world effect of antidepressants for depressive disorder in primary care: protocol of a population-based cohort study

    Thumbnail
    Date
    2020-06
    Author
    De Crescenzo, Franco
    Cipriani, Andrea
    Metadata
    Show full item record
    Citation
    Franco De Crescenzo,Cesar Garriga, Anneka Tomlinson, Carol Coupland, Orestis Efthimiou, Seena Fazel, Julia Hippisley-Cox, Andrea Cipriani. Real-world effect of antidepressants for depressive disorder in primary care: protocol of a population-based cohort study. Evidence-Based Mental Health 2020;23:122-126
    Abstract
    Introduction Clinical guidelines recommend antidepressants as the first line of treatment for adults with moderate-to-severe depression. Randomised trials provide the best evidence on the comparative effectiveness of antidepressants for depression, but are limited by a short follow-up and a highly selected population. We aim to conduct a cohort study on a large database to assess acceptability, efficacy, safety and tolerability of antidepressant monotherapy in people with depressive disorder in primary care. Methods and analysis This is a protocol for a cohort study using data from the QResearch primary care research database, which is the largest general practice research database in the UK. We will include patients registered for at least 1 year from 1 January 1998, diagnosed with a new episode of depression and on antidepressant and a comparison group not on antidepressant. The exposure of interest will be treatment with antidepressant medications. Our outcomes will be acceptability (treatment discontinuation due to any cause), efficacy (clinical response and remission); safety (adverse events (AEs) and all-cause mortality); and tolerability (dropouts due to any AE) measured at 2 months, 6 months and 1 year. For each outcome, we will estimate the absolute risks for all antidepressants, and relative effects between antidepressants using Cox’s proportion hazards models. We will calculate HRs and 99.9% CIs for each outcome of interest. Discussion The main limitation is the observational nature of our study, while the major strengths include the large representative population contained in QResearch and the possibly high generalisability
    URI
    https://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/553
    Published online at:
    http://dx.doi.org/10.1136/ebmental-2020-300149
    Collections
    • Depressive Disorders [87]

    Oxford Health copyright © 2019
    Contact Us | Send Feedback | JSPUI
    Powered by KnowledgeArc
     

     

    Browse

    All of ORKACommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsContributor DisciplineThis CollectionBy Issue DateAuthorsTitlesSubjectsContributor Discipline

    My Account

    Login

    Researcher Profiles

    Researchers

    Oxford Health copyright © 2019
    Contact Us | Send Feedback | JSPUI
    Powered by KnowledgeArc